|
|
TNK2 |
tyrosine kinase non receptor 2 |
|
- ATP
- Debromohymenialdisine
- Entrectinib
- Fostamatinib
|
|
|
|
TPTE |
transmembrane phosphatase with tensin homology |
- Synthesis of PIPs at the Golgi membrane
|
|
|
|
|
TRIP6 |
thyroid hormone receptor interactor 6 |
|
|
|
|
|
TYK2 |
tyrosine kinase 2 |
- Interleukin-6 signaling
- Interleukin-6 signaling
- MAPK3 (ERK1) activation
- MAPK1 (ERK2) activation
- Other interleukin signaling
- Interleukin-10 signaling
- Interleukin-4 and Interleukin-13 signaling
- IL-6-type cytokine receptor ligand interactions
- Interleukin-20 family signaling
- Interleukin-35 Signalling
- Interleukin-12 signaling
- Interleukin-12 signaling
- Interleukin-23 signaling
- Interleukin-23 signaling
- Interleukin-27 signaling
- Interleukin-27 signaling
- Interferon alpha/beta signaling
- Regulation of IFNA/IFNB signaling
- Regulation of IFNA/IFNB signaling
- Signaling by CSF3 (G-CSF)
- Signaling by CSF3 (G-CSF)
- Potential therapeutics for SARS
- Inactivation of CSF3 (G-CSF) signaling
- Inactivation of CSF3 (G-CSF) signaling
- SARS-CoV-2 activates/modulates innate and adaptive immune responses
- Signaling by ALK fusions and activated point mutants
- Evasion by RSV of host interferon responses
|
- 2-tert-butyl-9-fluoro-1,6-dihydrobenzo[h]imidazo[4,5-f]isoquinolin-7-one
- Ruxolitinib
- Tofacitinib
- Baricitinib
- Fostamatinib
- Abrocitinib
- Deucravacitinib
|
- Other well-defined immunodeficiency syndromes, including the following seven diseases: Wiskott-Aldrich syndrome; DiGeorge syndrome; Hyper-IgE syndrome; X-linked lymphoproliferative syndrome; Immunodeficiency, Polyendocrinopathy, Enteropathy, X-linked Syndrome (IPEX); Cartilage-Hair Hypoplasia; Autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED)
|
|
|
VAV1 |
vav guanine nucleotide exchange factor 1 |
- GPVI-mediated activation cascade
- GPVI-mediated activation cascade
- PIP3 activates AKT signaling
- Signaling by SCF-KIT
- NRAGE signals death through JNK
- Regulation of actin dynamics for phagocytic cup formation
- Constitutive Signaling by Aberrant PI3K in Cancer
- FCERI mediated MAPK activation
- FCERI mediated Ca+2 mobilization
- FCERI mediated Ca+2 mobilization
- CD28 dependent Vav1 pathway
- G alpha (12/13) signalling events
- VEGFA-VEGFR2 Pathway
- VEGFA-VEGFR2 Pathway
- Interleukin-3, Interleukin-5 and GM-CSF signaling
- VEGFR2 mediated vascular permeability
- PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
- RHOA GTPase cycle
- RAC1 GTPase cycle
- RAC2 GTPase cycle
- RHOG GTPase cycle
- Erythropoietin activates RAS
- Erythropoietin activates RAS
- Regulation of signaling by CBL
- FCGR3A-mediated phagocytosis
- FCGR3A-mediated phagocytosis
- Potential therapeutics for SARS
- Azathioprine ADME
- Antigen activates B Cell Receptor (BCR) leading to generation of second messengers
- Antigen activates B Cell Receptor (BCR) leading to generation of second messengers
|
|
|
|
|
YES1 |
YES proto-oncogene 1, Src family tyrosine kinase |
- Signaling by ERBB2
- Signaling by SCF-KIT
- Signaling by SCF-KIT
- Regulation of KIT signaling
- FCGR activation
- PECAM1 interactions
- EPH-Ephrin signaling
- Co-stimulation by CD28
- Co-inhibition by CTLA4
- EPHB-mediated forward signaling
- EPHB-mediated forward signaling
- EPHA-mediated growth cone collapse
- EPHA-mediated growth cone collapse
- EPH-ephrin mediated repulsion of cells
- RUNX2 regulates osteoblast differentiation
- Regulation of signaling by CBL
- Regulation of signaling by CBL
- FCGR3A-mediated IL10 synthesis
- FCGR3A-mediated phagocytosis
- Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants
- Signaling by CSF1 (M-CSF) in myeloid cells
|
|
|